文献速递泌尿男性生殖肿瘤

转移性前列腺癌中的胚系CDK12截短变异

Germline CDK12 variants in aggressive prostate cancer.
PubMed 文献 · Cancer Discov · 2026-07-02

在4,535例转移性前列腺癌患者中检出5例(0.1%)携带胚系CDK12截短变异,均伴体细胞CDK12第二变异及串联重复特征性基因组不稳定。胚系CDK12截短变异在转移性前列腺癌中富集(对比gnomAD对照OR 11.4,95%CI 3.6-27.8),提示其是致死性转移性前列腺癌的罕见驱动因素。

要点

  • 转移性前列腺癌中胚系CDK12截短变异占0.1%(5/4,535)。
  • 所有携带者均需体细胞CDK12第二变异驱动且呈串联重复特征。
  • 胚系CDK12截短变异与转移性前列腺癌风险显著相关。

核心结论

  • 胚系CDK12截短变异是致死性转移性前列腺癌的罕见驱动因素。

研究设计与样本

  • 在4,535例转移性前列腺癌患者中检测胚系CDK12截短变异。

主要发现

  • 5例患者(年龄44-62岁)携带胚系CDK12截短变异,均伴体细胞CDK12第二变异。
  • 2例患者存在多个独立的CDK12驱动肿瘤,各具不同体细胞CDK12第二变异。
  • 胚系CDK12截短变异对比gnomAD V4.1.0对照(n=807,162)OR 11.4(95%CI 3.6-27.8)。
  • 对比gnomAD V2.1.1非癌对照(n=134,187)OR 29.6(95%CI 6.8-28.6)。

关键数值与推荐

  • CDK12突变见于2-7%的转移性前列腺癌,既往认为均为体细胞突变。
  • 胚系CDK12截短变异在转移性前列腺癌中占0.1%(5/4,535)。

临床怎么用

  • 转移性前列腺癌患者可考虑胚系CDK12检测以识别罕见驱动事件。
  • 检出胚系CDK12截短变异时应结合体细胞CDK12第二变异及基因组不稳定特征综合判定。

局限性

  • 家族史仅在两个家系中确认胚系变异遗传。
  • 胚系CDK12截短变异在转移性前列腺癌中频率极低(0.1%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CDK12 mutations occur in 2-7% of metastatic prostate cancers (mPCa) and are considered to be exclusively somatic. Here, we identified five patients with mPCa (ages 44-62) harboring germline CDK12 truncating variants among 4,535 tested (0.1%). All had CDK12-driven cancers defined by an additional somatic CDK12 variant and the CDK12-specific hallmark genomic instability signature characterized by hundreds of tandem duplications. Two patients had multiple independent CDK12-driven tumors with distinct secondary somatic CDK12 variants. Germline CDK12 truncating variants were enriched in mPCa compared to gnomAD V4.1.0 controls (n=807,162; odds ratio 11.4, 95% CI 3.6-27.8) and V2.1.1 non-cancer controls (n=134,187; odds ratio 29.6; 95% CI 6.8-28.6). Family history revealed multiple related individuals with prostate or ovarian cancer, and germline variant inheritance was confirmed in the two tested pedigrees. Our data suggest that germline CDK12 truncating variants are a rare driver of lethal mPCa.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Tolmeijer SH, Maurice-Dror C, Sandhu S, et al. Germline CDK12 variants in aggressive prostate cancer. Cancer Discov. 2026. PMID: 42392870. doi:10.1158/2159-8290.CD-26-0084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。